

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 April 2025 (03.04.2025)



(10) International Publication Number
WO 2025/072246 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) C07K 7/64 (2006.01)

(21) International Application Number:
PCT/US2024/048282

(22) International Filing Date:
25 September 2024 (25.09.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/585,311 26 September 2023 (26.09.2023) US
63/588,115 05 October 2023 (05.10.2023) US
63/557,125 23 February 2024 (23.02.2024) US
63/640,506 30 April 2024 (30.04.2024) US

(71) Applicant: **ENTRADA THERAPEUTICS, INC.**
[US/US]; One Design Center Place, Suite 17-500, Boston,
Massachusetts 02210 (US).

(72) Inventors: **LI, Xiang**; One Design Center Place, Suite
17-500, Boston, Massachusetts 02210 (US). **LIAN, Wen-
long**; One Design Center Place, Suite 17-500, Boston,
Massachusetts 02210 (US). **QIAN, Ziqing**; One Design
Center Place, Suite 17-500, Boston, Massachusetts 02210
(US). **WASHBURN, Bergen**; One Design Center Place,
Suite 17-500, Boston, Massachusetts 02210 (US). **LEILI,
Steven**; One Design Center Place, Suite 17-500, Boston,
Massachusetts 02210 (US). **BARRETT, Jennifer**; One De-
sign Center Place, Suite 17-500, Boston, Massachusetts
02210 (US). **KENDERES, Kevin**; One Design Center
Place, Suite 17-500, Boston, Massachusetts 02210 (US).

(74) Agent: **PROVENCE, David** et al.; 111 Washington Av-
enue S., Suite 700, Minneapolis, Minnesota 55401 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: COMPOUNDS AND METHODS FOR SKIPPING EXON 50 IN DUCHENNE MUSCULAR DYSTROPHY

(57) Abstract: Described herein are EEV-cargo conjugates and compositions thereof comprising (a) an endosomal escape vehicle (EEV) comprising a cyclic cell penetrating peptide (cCPP); and (b) a cargo comprising an oligonucleotide that is complementary to a target sequence of a pre-mRNA transcript of a *DMD* gene, wherein the target sequence comprises at least a portion of the 5' flanking intron of exon 50, at least a portion of exon 50, at least a portion of the 3' flanking intron of exon 50, or a combination thereof. Also described herein are methods of treating DMD using the compounds described herein.

WO 2025/072246 A1